```html

Wernicke’s Encephalopathy – A Complete Medical Guide

Overview

Wernicke’s encephalopathy (WE) is an acute neurological disorder caused by a severe deficiency of thiamine (vitamin B1). The condition primarily affects the brain’s mammillary bodies, thalamus, and periaqueductal gray matter, leading to a classic triad of confusion, ocular motor dysfunction, and gait ataxia. If not treated promptly, WE can progress to irreversible damage known as Korsakoff syndrome, characterized by profound memory loss.

Who it affects

• Chronic alcohol users – the most common group, accounting for ~80 % of cases.<sup>[1]</sup>
• Individuals with **malnutrition** (e.g., severe dieting, eating disorders, bariatric surgery).
• Patients with conditions that impair thiamine absorption (e.g., gastrointestinal surgery, Crohn’s disease, HIV).
• People receiving prolonged intravenous glucose without thiamine supplementation (e.g., postoperative patients).

Prevalence

• In the United States, up to **2 % of chronic heavy drinkers** develop WE each year.<sup>[2]</sup>
• Hospital‑based studies report an incidence of **0.4–0.5 %** among all admissions, but autopsy data suggest many cases go unrecognized.<sup>[3]</sup>
• Globally, the exact prevalence is unknown, but regions with high alcohol consumption (Eastern Europe, parts of Asia) report higher rates.

Symptoms

The classic triad appears in only **≈30 %** of patients, so clinicians must consider a broader symptom spectrum.

Neurologic signs

• Confusion or altered mental status – ranging from mild inattention to stupor.
• Ophthalmoplegia – paralysis or weakness of the eye muscles, causing horizontal or vertical gaze palsy.
• Nystagmus – involuntary rapid eye movements, often horizontal but can be vertical or rotary.
• Ataxia – unsteady gait, difficulty walking in a straight line, or inability to stand without support.
• Peripheral neuropathy – tingling, burning, or weakness in hands/feet.

General and systemic features

• Memory impairment (early sign of evolving Korsakoff syndrome).
• Weakness or fatigue.
• Loss of appetite, nausea, or vomiting.
• Cardiovascular signs (tachycardia, hypotension) in severe malnutrition.

Rare or atypical manifestations

• Auditory hallucinations or dysarthria.
• Seizures (particularly in non‑alcoholic patients).
• Psychiatric symptoms such as agitation, depression, or psychosis.

Causes and Risk Factors

Underlying mechanism

Thiamine is a co‑factor for enzymes involved in glucose metabolism (pyruvate dehydrogenase, α‑ketoglutarate dehydrogenase, transketolase). Deficiency impairs cerebral energy production, leading to neuronal swelling, oxidative stress, and necrosis of vulnerable brain regions.

Primary causes

• Chronic alcohol consumption – interferes with thiamine absorption, storage, and utilization.<sup>[1]</sup>
• Malnutrition – inadequate dietary intake of thiamine (e.g., in refugees, homeless populations).
• Gastrointestinal surgery – bariatric or gastric bypass surgery reduces thiamine absorption.
• Prolonged IV glucose without thiamine supplementation increases demand and can precipitate WE.
• Hyperemesis gravidarum – severe, persistent vomiting in pregnancy leading to nutrient loss.
• Severe infections or critical illness – sepsis, malignancy, or ICU stays increase metabolic demand.

Risk factors

• Age > 50 years (though WE can occur at any age).
• Female sex – partly because of higher rates of eating disorders and certain surgeries.
• History of liver disease or pancreatic insufficiency.
• Use of diuretics or loop diuretics (may increase urinary thiamine loss).
• Genetic variants affecting thiamine transport (rare).

Diagnosis

No single test confirms WE; diagnosis is clinical, supported by laboratory and imaging studies.

Clinical criteria

Several sets of criteria are used. The most widely cited is the **Caine criteria** (1997), which require any two of the following:

1. Dietary deficiency or malnutrition.
2. Oculomotor abnormalities.
3. Cerebellar dysfunction (ataxia).
4. Altered mental status or memory impairment.

Meeting ≥2 criteria yields a sensitivity of 90 % and specificity of 70 %.<sup>[4]</sup>

Laboratory tests

• Serum thiamine level – measured via high‑performance liquid chromatography; low levels support the diagnosis but results can take days.
<
• Transketolase activity in red blood cells – reflects functional thiamine status; <10 % activity suggests deficiency.
• Baseline metabolic panel (electrolytes, glucose) to identify co‑existing abnormalities.

Neuroimaging

• MRI – most sensitive. Typical findings: symmetric hyperintensities on T2/FLAIR in the mammillary bodies, medial thalami, periaqueductal gray, and tectal plate.<sup>[5]</sup>
• CT scans are often normal early on and are primarily used to rule out hemorrhage or stroke.

Other assessments

• Neuropsychological testing – useful for documenting memory deficits and monitoring progression to Korsakoff syndrome.
• Electroencephalography (EEG) may show diffuse slowing but is not diagnostic.

Treatment Options

Prompt thiamine replacement is lifesaving. Treatment should begin **as soon as WE is suspected**, without waiting for laboratory confirmation.

Acute thiamine replacement

Regimen	Typical adult dose	Duration
IV thiamine 500 mg	Three times daily for 2–3 days	24–48 h
IV thiamine 250 mg	Every 8 h for 3–5 days	Until neurologic improvement
Oral thiamine	100 mg three times daily	After IV course, continue for at least 1 month

Guidelines from the European Federation of Neurological Societies (EFNS) and the American Society of Addiction Medicine recommend the high‑dose IV protocol above to ensure rapid brain penetration.<sup>[6]</sup>

Supportive care

• Correct hypoglycemia – give dextrose **after** thiamine to avoid precipitating WE.
• Hydration and electrolyte balance.
• Management of alcohol withdrawal (benzodiazepines) if needed.
• Nutrition counseling; start a thiamine‑rich diet (whole grains, legumes, pork, fortified cereals).

Adjunct therapies

• Magnesium supplementation – magnesium is a co‑factor for thiamine enzymes; low levels impair thiamine utilization.
• Physical and occupational therapy for gait and coordination deficits.
• Cognitive rehabilitation if memory impairment persists.

Long‑term management

After acute stabilization, patients usually require lifelong oral thiamine (100 mg daily) and regular follow‑up to monitor for relapse.

Living with Wernicke’s Encephalopathy

Daily management tips

• Medication adherence – set alarms or use pill organizers for daily thiamine.
• Balanced diet – incorporate thiamine‑rich foods (brown rice, beans, nuts, fortified breads).
• Alcohol moderation – abstinence is ideal; seek counseling or medication‑assisted treatment if needed.
• Monitoring – keep a symptom diary; report new confusion, balance problems, or vision changes immediately.
• Safety at home – remove trip hazards, install grab bars, and use a cane or walker as recommended.
• Regular medical review – at least every 3–6 months initially, then annually, to assess thiamine levels, nutritional status, and cognitive function.

Rehabilitation resources

Physical therapy programs focusing on gait training, balance exercises, and strength building are essential. Speech‑language pathologists can assist with memory strategies. Many hospitals offer outpatient neuro‑rehab clinics that tailor programs for WE survivors.

Prevention

• Prophylactic thiamine for high‑risk groups:
  • Alcohol‑dependent patients admitted to the hospital – 100 mg IV before any glucose infusion.
  • Patients undergoing bariatric or gastrointestinal surgery – 200–300 mg IV/PO peri‑operatively.
  • Pregnant women with hyperemesis gravidarum – 100 mg PO three times daily.
• Educate patients on the importance of a thiamine‑rich diet.
• Screen for malnutrition in primary‑care visits, especially in the elderly and those with chronic illnesses.
• In alcohol‑treatment programs, incorporate routine thiamine supplementation (e.g., 200 mg daily).
• Limit high‑dose glucose infusions without prior thiamine replacement.

Complications

If untreated or delayed, WE can lead to serious, often irreversible outcomes:

• Korsakoff syndrome – chronic amnestic disorder; patients retain confabulation and severe anterograde amnesia.
• Permanent ocular motor deficits (persistent nystagmus or diplopia).
• Chronic gait instability with increased fall risk.
• Seizures or status epilepticus.
• Psychiatric disorders (depression, anxiety, psychosis).
• Higher mortality – studies report in‑hospital mortality up to 20 % for severe WE.<sup>[7]</sup>

When to Seek Emergency Care

---

References

1. Harper C. Wernicke’s encephalopathy: a clinical review. Alcohol Alcohol. 2009;44(2):136‑40.
2. World Health Organization. Global status report on alcohol and health 2018.
3. Victor M, Adams RD, Collins GH. The Wernicke‑Korsakoff syndrome revisited. Alcohol Alcohol. 1991;26(3):315‑22.
4. Caine D, et al. The Caine criteria for diagnosing Wernicke’s encephalopathy. Alcohol Alcohol. 1997;32(5):659‑66.
5. Zuccoli G, et al. Diffusion‑weighted MR imaging in Wernicke’s encephalopathy. Neurology. 2007;68(3):207‑12.
6. European Federation of Neurological Societies. Guidelines on the treatment of Wernicke’s encephalopathy. 2010.
7. McGuigan C, et al. Mortality and long‑term outcomes in Wernicke’s encephalopathy: a systematic review. J Neurol Sci. 2021;422:117273.

```